Suputtamongkol Yupin, Kungpanichkul Nuntakorn, Silpasakorn Saowaluk, Beeching Nicholas J
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Int J Antimicrob Agents. 2008 Jan;31(1):46-9. doi: 10.1016/j.ijantimicag.2007.08.014. Epub 2007 Nov 26.
A prospective, randomised, open study compared a 7-day course of oral albendazole 800 mg daily with a single oral dose of the parenteral veterinary preparation of ivermectin in 42 Thai patients with chronic strongyloidiasis (21 in each group). The primary endpoints were relief of symptoms (if present) and clearance of Strongyloides larvae from faeces immediately after treatment and at follow-up to 16 weeks later. Cure rates in the albendazole and ivermectin groups were 38.1% and 76.2%, respectively, (P=0.029) in the intention-to-treat analysis and 50% and 88.9%, respectively, (P=0.023) in the per-protocol analysis. Acute generalised exanthematous pustulosis developed in one patient who was treated with the veterinary preparation of ivermectin. This study confirms the superiority of ivermectin compared with albendazole as well as that oral use of the parenteral veterinary preparation in humans is as effective and safe as human preparations.
一项前瞻性、随机、开放研究，将42例泰国慢性类圆线虫病患者（每组21例）每日口服800毫克阿苯达唑的7天疗程与单剂量口服兽用伊维菌素肠胃外制剂进行了比较。主要终点是症状缓解（若有症状）以及治疗后即刻和16周随访时粪便中类圆线虫幼虫的清除情况。在意向性分析中，阿苯达唑组和伊维菌素组的治愈率分别为38.1%和76.2%（P = 0.029），在符合方案分析中分别为50%和88.9%（P = 0.023）。接受兽用伊维菌素制剂治疗的1例患者发生了急性泛发性脓疱性皮疹。本研究证实了伊维菌素优于阿苯达唑，以及兽用肠胃外制剂口服用于人类与人类制剂一样有效且安全。
